Multi-Level Intervention for Colorectal Cancer Screening
(ACCSIS Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to boost colorectal cancer (CRC) screening in specific areas of Kentucky and Ohio. Researchers are testing a community-wide approach, called a multi-level intervention, involving clinics, healthcare providers, and local residents to determine if it increases CRC screening rates. The trial includes two groups: one receives the new program first, while the other starts later. Ideal candidates for this trial are individuals aged 50 to 74 living in the targeted counties of Appalachian Kentucky and Ohio. As an unphased trial, it offers participants the opportunity to contribute to innovative community health strategies that could enhance CRC screening rates.
Do I need to stop my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications.
What prior data suggests that this multi-level intervention is safe for increasing CRC screening?
Research shows that methods to increase colorectal cancer (CRC) screening are generally well-received. Studies on these methods have not identified any major safety issues. For example, one study reported over a 10% increase in screening rates without negative effects. Another study observed a 20.29% increase in CRC screening rates, also without safety concerns. These results suggest that the methods are safe for participants. Since these studies reported no adverse events, participants can usually join these programs without safety concerns.12345
Why are researchers excited about this trial?
Researchers are excited about this multi-level intervention for colorectal cancer (CRC) screening because it tackles the issue from several angles, potentially leading to higher screening rates. Unlike standard practices, which might focus solely on individual patient reminders or educational materials, this intervention integrates various strategies at multiple levels, such as enhancing provider recommendations, improving clinic workflows, and increasing patient engagement. By addressing barriers on multiple fronts, this approach could significantly boost early detection rates, improving patient outcomes and possibly saving lives.
What evidence suggests that this trial's multi-level intervention could be effective for increasing colorectal cancer screening?
Research has shown that using multiple strategies can greatly increase the number of people screened for colorectal cancer (CRC). One study found a 20.29% increase in CRC screenings with these strategies. Another study showed that screening rates rose from 27% to 40% when offering stool-based tests. Effective methods include mailing tests to individuals and assisting them in navigating the healthcare system. This trial will test a multi-level intervention that operates at various levels, such as clinics, healthcare providers, and the community, making it a promising way to improve screening rates. Participants in this trial may receive the intervention immediately or later in the project.12567
Who Is on the Research Team?
Mark B Dignan, PhD
Principal Investigator
University of Kentucky
Are You a Good Fit for This Trial?
This trial is for residents aged 50-74 in certain Appalachian counties of Kentucky and Ohio, regardless of their race, sex, or gender. It aims to help increase colorectal cancer screening rates in these communities.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Multi-level Intervention
Implementation of a multi-level intervention targeting clinics, providers, patients, and the community to increase CRC screening rates
Follow-up
Participants are monitored for changes in CRC screening rates and follow-up care
What Are the Treatments Tested in This Trial?
Interventions
- Multi-level intervention to increase CRC screening
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Kentucky
Lead Sponsor
National Cancer Institute (NCI)
Collaborator
Ohio State University
Collaborator